Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

146

projects in our pipeline

2

new molecular entity approvals in the last quarter

15

new molecular entities in our late-stage pipeline


Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Filter By:

Cardiovascular and Metabolic diseases (as at 4 February 2016)

Phase 1

Phase 1

  • AZD4076 non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH)
  • MEDI0382 diabetes/obesity
  • MEDI4166 diabetes/cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • MEDI6012 ACS

Phase 3/Reg.*

Phase 3/Reg.*

  • Brilinta/Brilique arterial thrombosis
  • Epanova severe hypertriglyceridaemia
  • Farxiga/Forxiga type-2 diabetes
  • ZS-9 (sodium-zirconium cyclosilicate) hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in CKD/ESRD

LCM Projects

LCM Projects

  • Brilinta/Brilique PEGASUS- TIMI 54 outcomes study in patients with prior myocardial infarction
  • Brilinta/Brilique EUCLID outcomes study in patients with peripheral artery disease
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique SOCRATES outcomes study in patients with stroke or TIA
  • Brilinta/Brilique THEMIS outcomes study in patients with type-2 diabetes and CAD, but without a previous history of MI or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon weekly suspension type-2 diabetes
  • Epanova STRENGTH outcomes study in statin-treated patients at high CV risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Epanova/Farxiga/Forxiga non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH)
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 type-2 diabetes outcomes study
  • Kombiglyze XR/Komboglyze type-2 diabetes
  • Onglyza SAVOR-TIMI 53 type-2 diabetes outcomes study
  • Xigduo XR/Xigduo type-2 diabetes
  • saxagliptin/dapagliflozin FDC type-2 diabetes

Oncology (as at 4 February 2016)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD5312 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD8835 solid tumours
  • AZD9150 haematological malignancies
  • AZD9496 ER+ breast cancer
  • Iressa + durvalumab NSCLC
  • MEDI-551 + rituximab haematological malignancies
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0639 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3617 solid tumours
  • MEDI4276 solid tumours
  • MEDI6383 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + MEDI6383 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + tremelimumab solid tumours

Phase 2

Phase 2

  • AZD1775 ovarian cancer
  • AZD2014 solid tumours
  • AZD3759 BLOOM Tagrisso (AZD9291) BLOOM brain metastases in advanced EGFRm NSCLC
  • AZD4547 solid tumours
  • AZD5069+durvalumab AZD9150+durvalumab SCCHN
  • AZD5363 breast cancer
  • MEDI-551 diffuse B-cell lymphoma
  • MEDI-573 metastatic breast cancer
  • durvalumab solid tumours
  • durvalumab + tremelimumab gastric cancer
  • savolitinib/ volitinib papillary renal cell carcinoma
  • selumetinib 2nd-line KRAS wt NSCLC

Phase 3/Reg.*

Phase 3/Reg.*

  • Tagrisso (AZD9291) AURA, AURA 2 ≥2nd-line advanced EGFRm T790M NSCLC
  • acalabrutinib B-cell blood cancers
  • cediranib ICON 6 PSR ovarian cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab HAWK 2nd-line SCCHN (PD-L1 positive)
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • selumetinib ASTRA differentiated thyroid cancer
  • selumetinib SELECT-1 2nd-line KRASm NSCLC
  • tremelimumab DETERMINE mesothelioma

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Lynparza (olaparib) prostate cancer
  • Lynparza (olaparib) GOLD 2nd-line gastric cancer
  • Lynparza (olaparib) OlympiA gBRCA adjuvant breast cancer
  • Lynparza (olaparib) OlympiAD gBRCA metastatic breast cancer
  • Lynparza (olaparib) POLO pancreatic cancer
  • Lynparza (olaparib) SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza (olaparib) SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza (olaparib) SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm NSCLC
  • Tagrisso (AZD9291) AURA 3 ≥2nd-line advanced EGFRm T790M NSCLC
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm NSCLC
  • Tagrisso (AZD9291)+durvalumab CAURAL ≥2nd-line advanced EGFRm T790M NSCLC

Respiratory, Inflammation and Autoimmunity (as at 4 February 2016)

Phase 1

Phase 1

  • AZD1419 asthma
  • AZD7986 COPD
  • AZD8871 COPD
  • AZD8999 COPD
  • AZD9567 rheumatoid arthritis
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI5872 SLE
  • MEDI7836 asthma
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • lesinurad+allopurinol chronic treatment of hyperuricemia in patients with gout

Phase 2

Phase 2

  • AZD7594 asthma/COPD
  • AZD7624 COPD
  • AZD9412 asthma/COPD
  • MEDI-551 neuromyelitis optica
  • MEDI2070 Crohn’s disease
  • MEDI9929 asthma/atopic dermatitis
  • PT010 asthma
  • RDEA3170 chronic treatment of hyperuricemia in patients with gout
  • abediterol (AZD0548) asthma/COPD
  • abrilumab Crohn’s disease / ulcerative colitis
  • anifrolumab lupus nephritis
  • mavrilimumab rheumatoid arthritis
  • tralokinumab atopic dermatitis

Phase 3/Reg.*

Phase 3/Reg.*

  • PT003 GFF PINNACLE COPD
  • PT010 COPD
  • Zurampic (lesinurad) CLEAR 1,2 CRYSTAL chronic treatment of hyperuricemia in patients with gout
  • anifrolumab TULIP systemic lupus erythematosus
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • brodalumab AMAGINE-1,2,3 psoriasis
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair COPD
  • Symbicort breath actuated Inhaler asthma/COPD
  • Symbicort SYGMA as needed use in mild asthma

Infection, Neuroscience and Gastrointestinal (as at 4 February 2016)

Phase 1

Phase 1

  • ATM AVI targeted serious bacterial infections
  • AZD8108 suicidal ideation
  • MEDI1814 Alzheimer’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia

Phase 2

Phase 2

  • AZD3241 multiple system atrophy
  • AZD3293 Alzheimer’s disease
  • CXL MRSA
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis

Phase 3/Reg.*

Phase 3/Reg.*

  • CAZ AVI serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • CAZ AVI hospital-acquired pneumonia/ ventilator-associated pneumonia
  • MEDI-550 pandemic influenza prophylaxis
  • Zinforo pneumonia/skin infections

LCM Projects

LCM Projects

  • Diprivan conscious sedation
  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Terminations